Completed OBSERVATIONAL NCT01320735

Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Leuprorelin (Lucrin Depot) in Patients With Advanced Prostate Cancer (PCa) in Russia

Prospective, Multi-Center, Observational Program to Assess Routine Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in the Russian Federation

Sponsor: AbbVie (prior sponsor, Abbott)

Conditions Prostate Cancer

Updated 6 times since 2017 Last updated: Jun 11, 2015 Started: Feb 28, 2011 Primary completion: May 31, 2014 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Prostate Cancer and is currently completed. AbbVie (prior sponsor, Abbott) leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Feb 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie (prior sponsor, Abbott)
Almedis

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.